Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets reduced its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 32.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,385 shares of the company's stock after selling 25,554 shares during the period. BNP Paribas Financial Markets owned 0.17% of Medpace worth $18,068,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of MEDP. R Squared Ltd acquired a new position in Medpace during the fourth quarter worth approximately $30,000. SBI Securities Co. Ltd. purchased a new stake in shares of Medpace during the 4th quarter valued at $31,000. Jones Financial Companies Lllp grew its stake in shares of Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after buying an additional 110 shares during the period. Lindbrook Capital LLC increased its holdings in shares of Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after buying an additional 29 shares during the last quarter. Finally, Assetmark Inc. raised its position in shares of Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after buying an additional 29 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Trading Down 5.9%

NASDAQ MEDP traded down $18.42 during trading hours on Wednesday, reaching $291.73. 608,763 shares of the company traded hands, compared to its average volume of 348,144. The stock has a market capitalization of $8.38 billion, a PE ratio of 23.10, a PEG ratio of 3.81 and a beta of 1.55. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $459.77. The company has a 50 day moving average of $306.29 and a two-hundred day moving average of $328.34.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $3.06 by $0.61. The business had revenue of $558.57 million for the quarter, compared to analysts' expectations of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same quarter last year, the company posted $3.20 earnings per share. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the business's stock in a transaction that occurred on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the sale, the director now directly owns 2,998 shares in the company, valued at approximately $904,856.36. The trade was a 36.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 20.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on MEDP shares. William Blair restated a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. Truist Financial reduced their price objective on Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a research note on Wednesday, April 23rd. Leerink Partnrs upgraded Medpace to a "hold" rating in a research note on Monday, March 24th. Robert W. Baird dropped their target price on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a report on Wednesday, April 23rd. Finally, Leerink Partners initiated coverage on Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target on the stock. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, Medpace currently has a consensus rating of "Hold" and an average target price of $349.30.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.